Cornerstone Capital Management Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-8,277	Closed	-$231K	–	1371
2016 Q1	$231K	Sell	8,277 -1,400	-14%	-$30.5K	﹤0.01%	1181
2015 Q4	$345K	Sell	9,677 -523	-5%	-$18.4K	﹤0.01%	1107
2015 Q3	$337K	Buy	10,200 +800	+9%	+$33.3K	﹤0.01%	1110
2015 Q2	$394K	Sell	9,400 -200	-2%	-$7.74K	﹤0.01%	1051
2015 Q1	$313K	Buy	9,600 +700	+8%	+$24.1K	﹤0.01%	1102
2014 Q4	$283K	Buy	8,900 +1,400	+19%	+$39.7K	﹤0.01%	1047
2014 Q3	$186K	Buy	+7,500	New	+$175K	﹤0.01%	1110

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Cornerstone Capital Management Holdings's ACAD Position: Q2 2016 in Review

Cornerstone Capital Management Holdings sold out of Acadia Pharmaceuticals (ACAD) in Q2 2016, closing a stake of 8,277 shares — an estimated $231K sold.

Cornerstone Capital Management Holdings first reported a position in ACAD in Q3 2014 and held it in 7 quarters. The position peaked at $394K in Q2 2015. 228 funds tracked by Wall St. Rank hold ACAD as of Q2 2016.

Cornerstone Capital Management Holdings reported no remaining Acadia Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Cornerstone Capital Management Holdings sold 8,277 Acadia Pharmaceuticals shares in Q2 2016, an estimated $231K.
Cornerstone Capital Management Holdings first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 7 quarters.
Cornerstone Capital Management Holdings's Acadia Pharmaceuticals position peaked at $394K in Q2 2015.
228 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2016.

Based on Cornerstone Capital Management Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.